Table 1.

Anti-CCP Positivity and Use of DMARDs at Baseline, by Race and Ethnicity, in a Subsample (n = 9,988) of Participants With Self-Reported Rheumatoid Arthritis (n = 15,188^a), Women's Health Initiative Rheumatoid Arthritis Study, 2009–2011

Reported History of RA and Ethnicity	Anti-CCP Positivity			DMARD Useb at Baseline			DMARD Useb at Any Time
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
RA reported at baseline
Black	1,160	149	12.8	1,159	77	6.6	1,160	106	9.1
Hispanic	367	41	11.2	367	21	5.7	367	30	8.2
White	4,127	422	10.2	4,130	363	8.8	4,130	498	12.1
Total	5,654c	612	10.8	5,656d	461	8.1	5,657	634	11.2
P value	0.039			0.013			0.003
RA reported at follow-up only
Black	1,282	86	6.7	1,283	11	0.9	1,283	51	4.0
Hispanic	691	25	3.6	691	2	0.3	691	18	2.6
White	2,354	89	3.8	2,357	18	0.8	2,357	138	5.9
Total	4,327c	200	4.6	4,331	31	0.7	4,331	207	4.8
P value	0.0001			0.332			0.001
Grand total
Black	2,442	235	9.6	2,442	88	3.6	2,443	157	6.4
Hispanic	1,058	66	6.2	1,058	23	2.2	1,058	48	4.5
White	6,481	511	7.9	6,487	381	5.9	6,487	636	9.8
Total	9,981c	812	8.1	9,987d	492	4.9	9,988	841	8.4
P value	0.002			<0.0001			<0.0001

Abbreviations: anti-CCP, anti-cyclic citrullinated peptide; DMARDs, disease-modifying antirheumatic drugs [excluding prednisone]; RA, rheumatoid arthritis.

^a Includes white, black, and Hispanic Women's Health Initiative participants who reported RA at baseline or follow-up and had available blood samples.

^b Excluding prednisone.

^c Information on anti-CCP status at baseline was missing for 7 women.

^d Information on DMARD use at baseline was missing for 1 woman.